CN Patent

CN114450288A — 4-喹啉酮抗细菌化合物

Assigned to Janssen R&D Ireland ULC · Expires 2022-05-06 · 4y expired

What this patent protects

本发明涉及以下化合物(I)，其中整体如说明书所定义，并且其中这些化合物可以用作药物，例如用于在结核病的治疗中使用(例如组合使用)。

USPTO Abstract

本发明涉及以下化合物(I)，其中整体如说明书所定义，并且其中这些化合物可以用作药物，例如用于在结核病的治疗中使用(例如组合使用)。

Drugs covered by this patent

bedaquiline-fumarate (BEDAQUILINE FUMARATE)

Patent Metadata

Patent number: CN114450288A
Jurisdiction: CN
Classification: —
Expires: 2022-05-06
Drug substance claim: No
Drug product claim: No
Assignee: Janssen R&D Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.